State of Michigan Retirement System 13F: New $4.7M Stake in IBRX

The State of Michigan Retirement System took a new position in ImmunityBio, Inc. (IBRX) by acquiring 500,000 shares valued at $4.72 million. This move was disclosed in a filing on October 27, 2026.

IBRX ImmunityBio, Inc.

$8.63 ▲ +327.23% year to date

1M 3M YTD

Daily close · Oct 27, 2026

What Changed in State of Michigan Retirement System's ImmunityBio Position

The fund opened this new position, which accounts for about 0.04% of its total reported value of $11.02 billion. This stake ranks 45th among the 966 positions held by the fund.

Other Institutional Activity in ImmunityBio

Shaw D.E. & Co., Inc. trimmed its holdings by 1,020,834 shares, ending with 11,551,019 shares worth approximately $99.7 million. Two Sigma Investments, LP added 6,711,591 shares, increasing its total to 11,097,106 shares valued at about $95.8 million. Millennium Management LLC grew its stake by 4,159,565 shares, bringing its total to 5,579,793 shares worth about $48.2 million.

ImmunityBio, Inc. Stock Up 5.0%

ImmunityBio's stock closed at $8.63 on October 27, 2026, which is about equal to its recent trading price. The stock is currently 30.6% below its 52-week high of $12.43, but it is 342.6% above its 52-week low of $1.95.

Recent Earnings

For the trailing twelve months, ImmunityBio reported revenue of $165.8 million, with a year-over-year revenue growth of 93.9%. The next earnings report is expected on November 3, 2026.

Insider Buying and Selling at ImmunityBio, Inc.

Several insiders have sold shares recently, including Director Christobel E. Selecky, who sold 159,478 shares at an average price of $9.02 on July 1, 2026, for a total of about $1.44 million. Another Director, Cheryl L Cohen, sold 131,210 shares at $9.50 on July 2, 2026, totaling around $1.25 million. A further sale by Cohen on October 2 involved 81,056 shares at $10.50, valued at approximately $851,088.

Analysts Set New Price Targets

On October 15, 2026, Jefferies maintained a 'Buy' rating on ImmunityBio with a price target of $14.00, up from a prior target of $12.00. HC Wainwright & Co. also reiterated a 'Buy' rating with a price target of $15.00, unchanged from before.

About ImmunityBio

ImmunityBio, Inc. is a biotechnology company based in San Diego, California. It focuses on developing immunotherapies aimed at activating the immune system to fight cancer and infectious diseases. This new investment reflects potential confidence in the company's innovative approaches in the healthcare sector.

Bottom Line

Investors will be watching ImmunityBio closely as it approaches its next earnings report on November 3, 2026. With a strong buy rating from analysts and significant institutional interest, the stock's future movements will be of keen interest.